KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $99.3 million.

  • Ionis Pharmaceuticals' Accumulated Expenses fell 2016.62% to $99.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year decrease of 2016.62%. This contributed to the annual value of $108.4 million for FY2024, which is 2667.86% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Accumulated Expenses stood at $99.3 million, which was down 2016.62% from $99.0 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Accumulated Expenses high stood at $147.9 million for Q4 2023, and its period low was $75.1 million during Q2 2021.
  • In the last 5 years, Ionis Pharmaceuticals' Accumulated Expenses had a median value of $106.0 million in 2024 and averaged $108.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 7875.72% in 2022, then plummeted by 2667.86% in 2024.
  • Ionis Pharmaceuticals' Accumulated Expenses (Quarter) stood at $88.6 million in 2021, then surged by 58.2% to $140.1 million in 2022, then rose by 5.56% to $147.9 million in 2023, then dropped by 26.68% to $108.4 million in 2024, then fell by 8.42% to $99.3 million in 2025.
  • Its Accumulated Expenses stands at $99.3 million for Q3 2025, versus $99.0 million for Q2 2025 and $102.7 million for Q1 2025.